TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05645107: A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Se

Sponsor: Grifols Therapeutics LLC · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 386 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$5,051,508

Rescue Site Savings

+$3,345,804

Unlock Full NCT05645107 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05645107 Rescue Dossier →